passage bio stock news

As a group analysts expect that Passage Bio will post -316 earnings per share for the current year. PASG a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous.

Passage Bio Site Design Web Design Bio

Stay up to date on the latest stock price chart news analysis fundamentals trading and investment tools.

. NASDAQPASG Get Rating was the target of a large growth in short. June 1 2022. Goldsmith bought 10000 shares of the stock in a transaction on Monday March 21st.

Get the latest Passage Bio Inc. During the same quarter in the prior year the company posted 076 earnings per share. Passage Bio undertakes no obligation to publicly update any forward-looking statement whether written or oral that may be made from time to time whether as a result of new information future developments or otherwise.

A high-level overview of Passage Bio Inc. The stock was purchased at an average price of 315 per share with a total value. PHILADELPHIA June 01 2022 GLOBE NEWSWIRE -- Passage Bio Inc.

Real time Passage Bio Inc. PASG stock price quote stock graph news analysis. Passage Bio owners buys 168300 shares worth 910K.

On average they anticipate Passage Bios stock price to reach 1700 in the next twelve months. The 13 analysts offering price forecasts for Passage Bio have a median target of 2462 with a high estimate of 4500 and a. This suggests a possible upside of 8444 from the stocks current price.

ET by Ciara Linnane. Passage Bio Announces Maxine Gowen PhD as Chairwoman of the Board of Directors. In 2014 GSK faced two back-to-back Phase III flops for the heart drug.

Ownership Submission FORM 4 Check this box if no longer. Learn more about Passage Bio. Posted by MarketBeat News on Jun 1st 2022.

Get the latest Passage Bio Inc PASG real-time quote historical performance charts and other financial information to help you make more informed trading and investment decisions. Discover what drives us. Find the latest Passage Bio Inc.

In other Passage Bio news major shareholder Orbimed Advisors Llc acquired 221500 shares of the businesss stock in a transaction on Tuesday May 3rd. Is followed by the analysts listed above. Stuart Henderson Passage Bio 267-866-0114 shenderson.

Passage Bio names new board chair following sudden death of Dr. Get Passage Bio Inc PASGNASDAQ real-time stock quotes news price and financial information from CNBC. The company is based in Philadelphia PA and has a research collaboration and license agreement with the University of Pennsylvania Penn and its Gene Therapy Program.

What are analysts forecasts for Passage Bio stock. Their forecasts range from 600 to 3400. Please note that any opinions estimates or forecasts regarding Passage Bio Incs performance made by these analysts are theirs alone and do not represent opinions forecasts or predictions of Passage Bio.

In other news CEO Bruce A. PASG stock quote history news and other vital information to help you with your stock trading and investing. For further information please contact.

PASG stock news and headlines to help you in your trading and investing decisions. View analysts price targets for Passage Bio or view top-rated stocks among Wall Street analysts. Passage Bio is a genetic medicines company focused on developing transformative therapies for central nervous system disorders with limited or no approved treatment options.

Passage Bios ambitions will be handled by a new face going forward as Bruce Goldsmith exited Tuesday. Genetic medicines company Passage Bio to offer 74 million shares in IPO priced at 16 to 18 each. 18 2020 at 653 am.

Passage Bio Inc 2022 Q1 Results Earnings Call Presentation Nasdaq Pasg Seeking Alpha